RT Journal Article
SR Electronic
T1 Assessing Willingness to receive COVID-19 Vaccines, associated factors and reasons for hesitancy among persons aged 13-80 years in Central Uganda. A population-based surveillance Cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.19.23288804
DO 10.1101/2023.04.19.23288804
A1 Daama, Alex
A1 Rashid, Naziru
A1 Asani, Kasango
A1 Nalwoga, Grace Kigozi
A1 Nalugoda, Fred
A1 Bulamba, Robert
A1 Kyasanku, Emmanuel
A1 Nakigozi, Gertrude
A1 Kigozi, Godfrey
A1 Kagaayi, Joseph
A1 Mugamba, Stephen
YR 2023
UL http://medrxiv.org/content/early/2023/04/23/2023.04.19.23288804.abstract
AB Background Vaccination is essential for controlling the COVID-19 pandemic. However adequate vaccine coverage is a critical to the effectiveness of the vaccine at a population level. Data on to acceptability of the vaccine in Urban areas are limited. This study examined the prevalence, factors associated with willingness to receive COVID-19 vaccine and reasons for hesitancy in the predominantly urban in central Uganda (Wakiso)Methods Data were obtained from a cross-sectional study conducted from March 1st, 2021, to September 30th, 2021 in the urban population-based cohort of the Africa Medical and behavioral Sciences Organization (AMBSO). Multivariable modified Poisson regression analysis was used to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals of willingness to accept the COVID-19 vaccine.Results A total of 1,903 participants were enrolled in the study; 61% of whom were females. About 63% of participants indicated willingness to accept the COVID-19 vaccine. Younger age groups (13-19 and 20-29) were less likely to accept the vaccine compared to the persons ages 40-49 years (aPR=0.79; 95% CI: 0.74, 0.84 for the 13-19 years and 0.93; 95% CI: 0.88, 0.98 for age group 20-29, compared to those ages 40–49 years. Post-primary education (aPR=1.05; 95% CI: 1.02, 1.09 compared to primary level), being a students and government staff (APR=1.13; 95% CI: 1.04, 1.23 compared to construction and Mechanic workers) were associated with willingness to receive COVID-19 vaccine. Some of the reported reasons for hesitancy included; concerns about side effects 154(57.0%), about 64(23.7%) did not think the vaccines were effective, and those who did not like the vaccines 32(11.9%).Conclusion A substantial proportion of individuals were not willingness to receive the COVID-19 vaccine. More effort is needed to reduce vaccine hesitancy, especially among the young and people with lower formal education.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was made possible by private funds from Ugandan AMBSO directors. No author received any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from all participants as per declaration of Helsinki ethical guidelines. The AMBSO-PHS protocol was reviewed and approved by Clarke International University Research and Ethics Committee (UG-REC-015- CIURE/0059) and registered with the Uganda National Council for Science and Technology. Only de-identified participant and household IDs are used to link all participant data, which is pseudonymized throughout. The information is then maintained in secure locations or on computers that only authorized specific AMBSO data managers and editors have access to.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData supporting the conclusions of this article can be accessed in the supporting information labelled as dataset and COVID 19 module_q'nnaire_Eng